Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports
- PMID: 38401232
- DOI: 10.1016/j.clineuro.2024.108183
Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports
Abstract
Introduction: Cases of Guillain-Barré Syndrome (GBS) have been believed to be associated with the novel COVID-19 infection, and also with the following vaccines developed against the infection. Our work aims to investigate the incidence of GBS after COVID-19 vaccination, and describe its clinical characteristics and potential confounders.
Methods: An electronic search was conducted through four databases: PubMed, Scopus, medRxiv, and Google Scholar for all case reports and case series describing after COVID-19 vaccine administration. All published articles from inception until November 1st, 2022 were included. Differences between groups were assessed using Pearson chi-square test. Modified Erasmus GBS Outcome Score (mEGOS) for the ability to walk after GBS was calculated for all cases with sufficient clinical data, and Kaplan-Meier survival analysis was performed to study the effect of vaccine type on the relationship between vaccination time and complication of GBS.
Results: About 103 studies describing 175 cases of GBS following COVID-19 vaccination were included. The Acute Inflammatory Demyelinating Polyradiculoneuropathy subtype was the most reported subtype with 74 cases (42.29%). The affected age group averaged around 53.59 ±18.83 years, with AMSAN occurring in a rather older group (63.88 ±20.87 years, p=0.049). The AstraZeneca vaccine was associated with AIDP (n=38, 21.71%) more than other vaccines, p=0.02. The bilateral facial palsy subtype was mostly linked to adenoviral vector vaccinations, accounting for an average of 72% of the total BFP cases. Dysesthesias was the most reported sensory complication (60%, p=0.349). Most GBS patients survived (96%, p=0.036), however, most patients had low mEGOS scores (4 ±3.57, p<0.01). On average, patients developed GBS at 13.43 ±11.45 days from vaccination (p=0.73), and survival analysis for complication of GBS into mechanical ventilation or walking impairment yielded a severely increased probability of complication after 25 days (p<0.01). Intravenous immunoglobulins (p=0.03) along with rehabilitation (p=0.19) were the most commonly used treatment.
Conclusion: This work investigates the incidence of Guillain-Barré Syndrome after COVID-19 vaccination. Most cases occurred after receiving the AstraZeneca or Pfizer vaccines, and despite low mortality rates, ambulation was compromised in most patients. A higher risk of GBS complication is associated with an onset later than 12-13 days, particularly with Pfizer, AstraZeneca, and Moderna vaccines. No specific predisposing or prognostic factor was identified, and the relation between the COVID-19 vaccines and GBS remain unclear.
Keywords: Autoimmunity; COVID-19; Guillain-Barré Syndrome; SARS-CoV-2; Vaccines.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no conflicts of interest to declare.
Similar articles
-
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.Immunol Res. 2022 Dec;70(6):752-764. doi: 10.1007/s12026-022-09316-6. Epub 2022 Sep 13. Immunol Res. 2022. PMID: 36098903 Free PMC article. Review.
-
Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.Vaccine. 2022 Dec 12;40(52):7579-7585. doi: 10.1016/j.vaccine.2022.10.084. Epub 2022 Nov 7. Vaccine. 2022. PMID: 36357291 Free PMC article.
-
COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.Brain. 2023 Feb 13;146(2):739-748. doi: 10.1093/brain/awac067. Brain. 2023. PMID: 35180300 Free PMC article.
-
COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.J Neurol Sci. 2022 Sep 15;440:120330. doi: 10.1016/j.jns.2022.120330. Epub 2022 Jun 25. J Neurol Sci. 2022. PMID: 35802961 Free PMC article.
-
Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.Hum Vaccin Immunother. 2023 Dec 31;19(1):2171231. doi: 10.1080/21645515.2023.2171231. Epub 2023 Feb 22. Hum Vaccin Immunother. 2023. PMID: 36919452 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous